ICTCAR-032

N/A

Report date: 2025/01/26 17:39:37

Base Information

Drug NameICTCAR-032
Drug Alias Nameanti-BCMA CAR T-cell therapy (Innovative Cellular Therapeutics)ICTCAR-032
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulators
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovative Cellular Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovative Cellular Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A